These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1313 related articles for article (PubMed ID: 28851662)

  • 1. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
    Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
    Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
    Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
    Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
    Miyazawa T; Marushima H; Saji H; Kojima K; Hoshikawa M; Takagi M; Nakamura H
    Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):1-9. PubMed ID: 30282880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.
    Cheng S; Zheng J; Zhu J; Xie C; Zhang X; Han X; Song B; Ma Y; Liu J
    Int J Biol Markers; 2015 Nov; 30(4):e364-8. PubMed ID: 26349666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.